GlaxoSmithKline (GSK) has taken control of Swiss company GlycoVaxyn in a $190m deal that bolsters its early vaccines pipeline.
GSK already owned a stake in GlycoVaxyn and had been working with the company since 2012 on the development of conjugate vaccines for bacterial infections.
{iframe}http://www.pmlive.com/pharma_news/gsk_buys_vaccine_specialist_glycovaxyn_for_$190m_647811{/iframe}